Cancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
Mol Cancer Res. 2012 Jul;10(7):958-68. doi: 10.1158/1541-7786.MCR-11-0616. Epub 2012 May 9.
Malignant glioblastomas are characterized by their ability to infiltrate into normal brain. We previously reported that binding of the multifunctional cytokine TNF-like weak inducer of apoptosis (TWEAK) to its receptor fibroblast growth factor-inducible 14 (Fn14) induces glioblastoma cell invasion via Rac1 activation. Here, we show that Cdc42 plays an essential role in Fn14-mediated activation of Rac1. TWEAK-treated glioma cells display an increased activation of Cdc42, and depletion of Cdc42 using siRNA abolishes TWEAK-induced Rac1 activation and abrogates glioma cell migration and invasion. In contrast, Rac1 depletion does not affect Cdc42 activation by Fn14, showing that Cdc42 mediates TWEAK-stimulated Rac1 activation. Furthermore, we identified two guanine nucleotide exchange factors (GEF), Ect2 and Trio, involved in TWEAK-induced activation of Cdc42 and Rac1, respectively. Depletion of Ect2 abrogates both TWEAK-induced Cdc42 and Rac1 activation, as well as subsequent TWEAK-Fn14-directed glioma cell migration and invasion. In contrast, Trio depletion inhibits TWEAK-induced Rac1 activation but not TWEAK-induced Cdc42 activation. Finally, inappropriate expression of Fn14 or Ect2 in mouse astrocytes in vivo using an RCAS vector system for glial-specific gene transfer in G-tva transgenic mice induces astrocyte migration within the brain, corroborating the in vitro importance of the TWEAK-Fn14 signaling cascade in glioblastoma invasion. Our results suggest that the TWEAK-Fn14 signaling axis stimulates glioma cell migration and invasion through two GEF-GTPase signaling units, Ect2-Cdc42 and Trio-Rac1. Components of the Fn14-Rho GEF-Rho GTPase signaling pathway present innovative drug targets for glioma therapy.
恶性神经胶质瘤的特征是其能够浸润到正常大脑中。我们之前曾报道,多功能细胞因子 TNF 样弱凋亡诱导因子(TWEAK)与其受体成纤维细胞生长因子诱导的 14 (Fn14)结合,通过 Rac1 的激活诱导神经胶质瘤细胞侵袭。在这里,我们表明 Cdc42 在 Fn14 介导的 Rac1 激活中起着至关重要的作用。TWEAK 处理的神经胶质瘤细胞显示 Cdc42 的激活增加,并且使用 siRNA 耗尽 Cdc42 会消除 TWEAK 诱导的 Rac1 激活,并阻止神经胶质瘤细胞迁移和侵袭。相反,Rac1 的耗竭不会影响 Fn14 引起的 Cdc42 激活,表明 Cdc42 介导 TWEAK 刺激的 Rac1 激活。此外,我们鉴定了两种参与 TWEAK 诱导的 Cdc42 和 Rac1 激活的鸟嘌呤核苷酸交换因子(GEF),Ect2 和 Trio。Ect2 的耗竭消除了 TWEAK 诱导的 Cdc42 和 Rac1 的激活,以及随后的 TWEAK-Fn14 定向神经胶质瘤细胞迁移和侵袭。相比之下,Trio 的耗竭抑制了 TWEAK 诱导的 Rac1 激活,但不抑制 TWEAK 诱导的 Cdc42 激活。最后,使用 RCAS 载体系统在 G-tva 转基因小鼠中的胶质特异性基因转移体内在小鼠星形胶质细胞中过度表达 Fn14 或 Ect2,诱导星形胶质细胞在大脑内迁移,证实了 TWEAK-Fn14 信号级联在神经胶质瘤侵袭中的体外重要性。我们的结果表明,TWEAK-Fn14 信号轴通过两个 GEF-GTPase 信号单元 Ect2-Cdc42 和 Trio-Rac1 刺激神经胶质瘤细胞迁移和侵袭。Fn14-Rho GEF-Rho GTPase 信号通路的组成部分为神经胶质瘤治疗提供了创新的药物靶点。